CTOs on the Move

Current Health

www.currenthealth.com

 
Current Health offers an enterprise care-at-home platform to enable healthcare organizations to deliver high-quality, patient-centric care at a lower cost. The company integrates patient-reported data with data from biosensors – including their own continuous monitoring wearable device – to provide healthcare organizations with actionable, real-time insights into the patient’s condition. Leveraging clinical algorithms that can be tailored to the individual patient, Current Health identifies when a patient needs clinical attention, allowing organizations to manage patient care remotely or coordinate in-home care via our integrated service partners. The Current Health platform brings together telehealth capabilities, patient engagement tools, and in-home connectivity ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details
Mark Kaufman
Chief Technology Officer Profile

Funding

Current Health raised $11.5M on 12/10/2019
Current Health raised $43M on 04/22/2021

Similar Companies

Access Health CT

Access Health CT is bringing the benefits of Health Care Reform to Connecticut. As the state`s official health insurance marketplace, we`re making it easier and more affordable for individuals, families, and small businesses to get quality health care coverage.

World Class Health and Fitness

World Class Health and Fitness is a Waukesha, WI-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Shepeard Community Blood Ctr

Shepeard Community Blood Ctr is a Augusta, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Data R X Management

Data R X Management is a Cumming, GA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

TherOx

TherOx, Inc. (TherOx) is a private, venture-financed medical device company based in Irvine, California, dedicated to elevating the standard of care for treatment of heart attack patients. A heart attack is caused when an artery in the heart becomes blocked. Current treatment of heart attack is to reestablish blood flow in the blocked artery as quickly as possible. Typically, this is done with a combination of medication and a percutaneous coronary intervention (PCI) which may include the placement of a (intracoronary) stent. PCI successfully restores blood flow, but damage to the patient’s heart remains. Blood flow in the microvasculature downstream from the blockage is compromised, and critical heart muscle tissue is damaged – or infarcted – due to oxygen deprivation brought on by the heart attack. The intent of SuperSaturated Oxygen (SSO2) Therapy from TherOx is to salvage damaged heart tissue by placing a high concentration of oxygen (~760 – 1,000 mmHg, or 5 – 7 times normal levels) into the patient’s blood plasma and delivering it directly to the area impacted by the heart attack. SSO2 Therapy serves as a complement to PCI and stenting. Immediately following the interventional procedure, proprietary technology from TherOx mixes a pre-specified concentration of “SuperOxygenated” saline solution with the patient’s blood to produce SuperOxygenated blood. The SuperOxygenated blood is then delivered through a catheter to the oxygen deficient tissue. Company research has confirmed in clinical studies that SuperSaturated Oxygen Therapy has the potential to reverse ischemia and may resuscitate tissue that may otherwise die. SSO2 Therapy circulates the patient`s own blood via the existing arterial access site used for the stenting procedure. Thus, no new access site is required. The TherOx DownStream System and DownStream Cartridge bear the CE Mark but are not available for commercial distribution in the EU at this time.